Research Perspectives:

MEK inhibitors in non-V600 BRAF mutations and fusions

Douglas B. Johnson _, Caroline A. Nebhan and Marcus S. Noel

PDF  |  Full Text  |  How to cite

Oncotarget. 2020; 11:3900-3903. https://doi.org/10.18632/oncotarget.27788

Metrics: PDF 1654 views  |   Full Text 2404 views  |   ?  


Douglas B. Johnson1, Caroline A. Nebhan1 and Marcus S. Noel2

1 Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA

2 Department of Medicine, Georgetown University Medical Center, Washington, DC, USA

Correspondence to:

Douglas B. Johnson,email: [email protected]

Keywords: trametinib; MEK; BRAF; atypical; fusion

Received: October 09, 2020     Accepted: October 13, 2020     Published: November 03, 2020

Copyright: © 2020 Johnson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27788